MedPath

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

Not Applicable
Completed
Conditions
Prostate Cancer
Registration Number
NCT01040624
Lead Sponsor
University of Florida
Brief Summary

The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
77
Inclusion Criteria

* Adenocarcinoma of the prostate.

Exclusion Criteria
  • Previous prostate cancer treatment such as chemotherapy and/or pelvic radiation.
  • Active inflammatory bowel disease (diverticulitis, Crohn's disease or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed.)
  • History of hip replacement.
  • Prior intrapelvic surgery. This includes the following:
  • Transrectal or rectal surgery other than polypectomy or hemorrhoid removal or banding
  • Transabdominal pelvic surgery
  • Bladder surgery
  • Prior myocardial infarction (MI) or congestive heart failure (CHF).
  • Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Acute Grade 3 or Higher Treatment-related Toxicity Rate.6 months after the completion of radiation therapy

Number of participants that experienced acute grade 3 or higher, treatment-related toxicity based on CTCAE version 3.0 criteria.

Secondary Outcome Measures
NameTimeMethod
Collect and Analyze Quality of Life, Treatment-related Late Morbidity, Disease Control, and Survival Outcome Parameters.After radiation: every 6 months for 3 years, then annually for 20 years
Collect and Analyze Treatment, Biologic and Diagnostic Information That May Impact Quality of Life, Disease Control, Morbidity and/or Survival Outcomes.After radiation: every 6 months for 3 years, then annually for 20 years

Trial Locations

Locations (1)

University of Florida Proton Therapy Institute

🇺🇸

Jacksonville, Florida, United States

University of Florida Proton Therapy Institute
🇺🇸Jacksonville, Florida, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.